NCT06171880

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901

An Open-label, Randomized, Single Administration, Full Replicated Crossover Phase 1 Clinical Trial to Compare Pharmacokinetics and Safety Between JLP-1901 and JC-001 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Jeil Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and pharmacokinetic characteristics after the administration of JC-001 and JLP-1901

Detailed description

An open-label, randomized, single administration, full replicated crossover phase 1 clinical trial to compare pharmacokinetics and safety between JLP-1901 and JC-001 in healthy subjects

Conditions

• Healthy Adult

Interventions

Type	Name	Description
DRUG	JLP-1901	administration of JLP-1901
DRUG	JC-001(active comparator)	administration of JC-001(tenofovir)

Timeline

• Start date: 2022-02-15
• Primary completion: 2022-03-11
• Completion: 2022-05-13
• First posted: 2023-12-15
• Last updated: 2023-12-15

Locations

1 site across 1 country: South Korea